Track topics on Twitter Track topics that are important to you
Antony Mattessich has formally started as CEO of Ocular Therapeutix and his first move as top executive is culling the company’s headcount by 19 percent. Bedford, MA-based Ocular (NASDAQ: OCUL), whose eye drug delivery device was recently rejected by the FDA, announced last month that Mattessich would succeed Amarpreet Sawhney as CEO. Upon the change, […]
Original Article: Mattessich Starts as New Ocular CEO, Trims Staff in Cost-Saving MoveNEXT ARTICLE
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals. <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...